Pfenex Reports Second Quarter 2016 Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to Pfenex Reports Second Quarter 2016 Results and Provides Business Update
August 8, 2016 7:33 AM EDT
Pfenex (NYSE: PFNX) reported Q2 EPS of ($0.43), $0.04 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $2.55 million.
For earnings history and earnings-related data on Pfenex (PFNX) click here.
...
More
August 8, 2016 7:32 AM EDT
Pfenex Inc. (NYSE: PFNX) announced positive immunogenicity and safety data from the Day 70 analysis of the Px563L anthrax vaccine study. The results demonstrate tolerable safety and significant immunogenicity after only 2 doses of Px563L.
"The Px563L data from the Day 70 analysis of the phase 1 study are very encouraging, with the vaccine being well-tolerated and affording potentially superior protection after only 2 doses," noted Dr. Hubert Chen, chief medical officer of Pfenex. Bertrand C. Liang, chief executive officer added, "These positive anthrax vaccine findings are a strong validation of our close... More
